Innovations for a healthier tomorrow

Follow us

Welcome to Achilles Vaccines



mOMV (modified Outer Membrane Vesicles) are the powerful, safe, highly immunogenic and versatile core vaccine platform used by Contraria Biotech. mOMV are shed by the bacteria following blebbing of the outer membrane and are able to deliver protective antigens to the immune system.  mOMV belong to the class of “non-living vaccines” and stimulate both innate and acquired protective immunity against pathogens with no signs of infection. mOMV act both as carriers for antigens from infectious agents and as immune-stimulants able to induce qualitatively superior protective immune responses.

mOMV can be easily manipulated to increase their yield and to deliver antigens from multiple pathogens, therefore leading to multivalent vaccines with fast production, low costs, low manufacturing footprint, easy scalability, sustainability of supply, all critical advantages while responding to known and unknown disease threat situations.

mOMV can be used to develop vaccines against bacteria, viruses, protozoa, parasites and tumors. This platform is ideally suited to rapidly respond to emerging or re-emerging disease threats and to fight the increasingly grave issue of antimicrobial resistance.

During their growth, Gram-negative bacteria naturally release outer membrane vesicles (OMV). These are blebs that resemble the composition and orientation of the bacterial outer surface.

OMV contain phospholipids, lipopolysaccharide, outer membrane proteins, and entrapped soluble periplasmic components.

OMV have been shown to be safe and highly immunogenic as vaccines in animal and human models, as they are intrinsically capable of stimulating both innate and adaptive immunity.

mOMV are powerful, cost effective and versatile vaccine platforms in as much as they are easy to manufacture and can induce optimal protective responses.  Furthermore, the level of membrane antigens can be genetically regulated and heterologous antigens from other pathogens can be incorporated in the vaccine and delivered to the immune system, thus providing a system to generate multivalent vaccine platforms.

LAB 4.0


Contraria Biotech is at the forefront in the use of the industry 4.0 concept for research and product development. Through collaborations with leading informatics companies and the University of Siena, Contraria Biotech is optimizing a revolutionary laboratory, based on interconnectivity, automation, machine learning, real-time data and robotics. This allows data acquisition, creation and exploitation based on Artificial Intelligence approaches.

This revolutionary approach allows educated predictions and precise decision making during the experimental phase (e.g. antigen selection, choice of expression systems), as well as optimised product development and production at the later stages.

Contraria Biotech Lab 4.0 represents a new paradigm for the early-stage development of new biopharmaceutical products and will open-up new opportunities in the pharmaceutical industry.

This is realized in Contraria Biotech using lab equipment fully interconnected through an IoT platform to simplify data collection, data analysis and the use of computerized logical-mathematical tools (algorithms) for a “product development by design” based on an advanced AI/ML/DoE platform

 Contraria Biotech Lab 4.0 aims at:

  1. Reducing R&D costs through the Quality by Design approach
  2. Speeding up laboratory research through exploitation of available data/information
  3. Generating and exploiting mathematical predictions for the selection of optimal research approaches/pathways
  4. Multidisciplinary teamwork boosting innovation: IT, math, biotech scientists